TeamDrive
RUS

Russias drugs exports in January November 2017 amounted to 19 billion rubles

12 January 2018

GMP News

In the first 11 months of 2017, the exports of medicinal products from Russia (excluding the shipments to EAEU) reached 19.0 billion rubles (including the customs duties). This means that, when calculated in the Russian currency, the increase over the same period of 2016 was only 0.4%. However, the mere fact of positive dynamics is quite encouraging, as the results for January-October were much gloomier (at that time, the long-term growth rate was -2.2%).

The active efforts of exporters reversed the situation in November 2017. For that month, the total exports of medicinal products from Russia reached 2.3 billion rubles, an increase was 23% in ruble terms. Although this was not a record-breaking result, it is still quite outstanding, since better dynamics have been demonstrated by exporters only in January 2017, when the shipments increased by 58%.

In physical terms, the exports in November 2017 amounted to 70.8 million packages, a 22% increase year over year. Moreover, throughout the year, the general dynamics in physical terms can be described as rather successful. Despite occasional downturns reported, for example, for February when the exports in terms of shipped packages fell by 38%, the overall results for the first 11 months of 2017 have been markedly positive (+7.3%). Since the beginning of 2017, the total exports of medicinal products from Russia reached 536.4 million packages.


Previous publication Next publication

Media Center

  • 31 October 2018

    Scientists unveiled a more effective approach for assessing drug response

    Scientists from Eli Lilly and Company, the Icahn School of Medicine at Mount Sinai (New York, USA) and Sema4 (Stamford, USA) released results from a proof-of-concept study demonstrating that patient-derived cells offer a more effective approach for assessing drug response than conventional methods.

  • 30 October 2018

    Researchers developed an AI approach to identify antibiotic resistance genes

    Researchers at the University of California San Diego (USA) have developed an approach that uses machine learning to identify and predict which genes make infectious bacteria resistant to antibiotics. The approach was tested on strains of Mycobacterium tuberculosis – the bacteria that cause tuberculosis (TB) in humans. It identified 33 known and 24 new antibiotic resistance genes in these bacteria.

  • 29 October 2018

    Expanding the reach of gene editing with a new CRISPR enzyme

    The CRISPR-Cas9 gene editing system has been widely studied because of its potential therapeutic applications, but limitations in the number of locations on the genome it can target remain a major drawback. Now scientists at the Massachusetts Institute of Technology have identified a new Cas9 enzyme that they say can help CRISPR reach more gene mutations.

  • 26 October 2018

    Biotech Backed by Bain, Pfizer loads prime CNS assets into new biotech

    Pfizer has followed through on its pledge to divest a hunk of its neuroscience R&D, spinning several programs into a new company called Cerevel Therapeutics backed by $350 million in venture funding. Pfizer is contributing a trio of clinical-stage drug candidates—including a Parkinson’s therapy due to start phase 3 testing next year—plus a clutch of earlier-stage programs, while Bain Capital and affiliates stumped up the initial funding.

Read more